These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 22094980)
1. Biotransformation of BMOV in the presence of blood serum proteins. Sanna D; Bíró L; Buglyó P; Micera G; Garribba E Metallomics; 2012 Jan; 4(1):33-6. PubMed ID: 22094980 [TBL] [Abstract][Full Text] [Related]
2. New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals. Liboiron BD; Thompson KH; Hanson GR; Lam E; Aebischer N; Orvig C J Am Chem Soc; 2005 Apr; 127(14):5104-15. PubMed ID: 15810845 [TBL] [Abstract][Full Text] [Related]
3. Transport of the anti-diabetic VO2+ complexes formed by pyrone derivatives in the blood serum. Sanna D; Bíró L; Buglyó P; Micera G; Garribba E J Inorg Biochem; 2012 Oct; 115():87-99. PubMed ID: 22926028 [TBL] [Abstract][Full Text] [Related]
4. Calorimetric studies of the interaction between the insulin-enhancing drug candidate bis(maltolato)oxovanadium(IV) (BMOV) and human serum apo-transferrin. Bordbar AK; Creagh AL; Mohammadi F; Haynes CA; Orvig C J Inorg Biochem; 2009 Apr; 103(4):643-7. PubMed ID: 19056126 [TBL] [Abstract][Full Text] [Related]
5. Effect of vanadium(IV) compounds in the treatment of diabetes: in vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovandium(IV). Willsky GR; Goldfine AB; Kostyniak PJ; McNeill JH; Yang LQ; Khan HR; Crans DC J Inorg Biochem; 2001 May; 85(1):33-42. PubMed ID: 11377693 [TBL] [Abstract][Full Text] [Related]
6. Speciation studies of vanadium in human liver (HepG2) cells after in vitro exposure to bis(maltolato)oxovanadium(IV) using HPLC online with elemental and molecular mass spectrometry. Nischwitz V; Davies JT; Marshall D; González M; Gómez Ariza JL; Goenaga-Infante H Metallomics; 2013 Dec; 5(12):1685-97. PubMed ID: 24136403 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of protein tyrosine phosphatase 1B and alkaline phosphatase by bis(maltolato)oxovanadium (IV). Li M; Ding W; Baruah B; Crans DC; Wang R J Inorg Biochem; 2008 Oct; 102(10):1846-53. PubMed ID: 18728000 [TBL] [Abstract][Full Text] [Related]
8. Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component. Peters KG; Davis MG; Howard BW; Pokross M; Rastogi V; Diven C; Greis KD; Eby-Wilkens E; Maier M; Evdokimov A; Soper S; Genbauffe F J Inorg Biochem; 2003 Aug; 96(2-3):321-30. PubMed ID: 12888267 [TBL] [Abstract][Full Text] [Related]
9. A new salicylic acid-derivatized kojic acid vanadyl complex: synthesis, characterization and anti-diabetic therapeutic potential. Wei Y; Zhang C; Zhao P; Yang X; Wang K J Inorg Biochem; 2011 Aug; 105(8):1081-5. PubMed ID: 21726771 [TBL] [Abstract][Full Text] [Related]
10. Interaction of antidiabetic vanadium compounds with hemoglobin and red blood cells and their distribution between plasma and erythrocytes. Sanna D; Serra M; Micera G; Garribba E Inorg Chem; 2014 Feb; 53(3):1449-64. PubMed ID: 24437949 [TBL] [Abstract][Full Text] [Related]
11. New developments in the comprehension of the biotransformation and transport of insulin-enhancing vanadium compounds in the blood serum. Sanna D; Micera G; Garribba E Inorg Chem; 2010 Jan; 49(1):174-87. PubMed ID: 19947643 [TBL] [Abstract][Full Text] [Related]
12. Characterization and biotransformation in the plasma and red blood cells of V(IV)O(2+) complexes formed by ceftriaxone. Sanna D; Fabbri D; Serra M; Buglyó P; Bíró L; Ugone V; Micera G; Garribba E J Inorg Biochem; 2015 Jun; 147():71-84. PubMed ID: 25601642 [TBL] [Abstract][Full Text] [Related]
13. On the transport of vanadium in blood serum. Sanna D; Micera G; Garribba E Inorg Chem; 2009 Jul; 48(13):5747-57. PubMed ID: 19514735 [TBL] [Abstract][Full Text] [Related]
14. Molecular mechanism of bis(maltolato)oxovanadium(IV)-induced insulin signaling in 3T3-L1 and IM9 cells: impact of dexamethasone. Bose S; Farah MA; Jung HC; Lee JH; Kim Y J Mol Endocrinol; 2007 Jun; 38(6):627-49. PubMed ID: 17556533 [TBL] [Abstract][Full Text] [Related]
15. Interaction of VO2+ ion and some insulin-enhancing compounds with immunoglobulin G. Sanna D; Micera G; Garribba E Inorg Chem; 2011 Apr; 50(8):3717-28. PubMed ID: 21434616 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and characterization of V(IV)O complexes of picolinate and pyrazine derivatives. Behavior in the solid state and aqueous solution and biotransformation in the presence of blood plasma proteins. Koleša-Dobravc T; Lodyga-Chruscinska E; Symonowicz M; Sanna D; Meden A; Perdih F; Garribba E Inorg Chem; 2014 Aug; 53(15):7960-76. PubMed ID: 25013935 [TBL] [Abstract][Full Text] [Related]
17. Characterization of the Potent Insulin Mimetic Agent Bis(maltolato)oxovanadium(IV) (BMOV) in Solution by EPR Spectroscopy. Hanson GR; Sun Y; Orvig C Inorg Chem; 1996 Oct; 35(22):6507-6512. PubMed ID: 11666798 [TBL] [Abstract][Full Text] [Related]
18. A quantitative study of the biotransformation of insulin-enhancing VO(2+) compounds. Sanna D; Buglyó P; Micera G; Garribba E J Biol Inorg Chem; 2010 Aug; 15(6):825-39. PubMed ID: 20339887 [TBL] [Abstract][Full Text] [Related]